IL21
Interleukin-21
As of the edition of 20 October 2026, IL21 (interleukin-21, UniProt Q9HBE4) has 2 drugs tested at it and 2 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9HBE4
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- Secreted
- Solved structures
- 3
- Disease areas
- Immune system; Skin and connective tissue; Bones, joints and muscles; Digestive system; Hormones; Nutrition and metabolism
- Registered trials of its drugs
- 7
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| NNC0114-0006 | Went quiet | Phase 2 | none listed |
| Avizakimab | Went quiet | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Novo Nordisk | Route A |
| Boston Pharmaceuticals | Route A |
The other 0 companies at IL21
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at IL21, ranked, with the facts behind eachRequest access. Nothing is shown until you do.